IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Pharma/fine chemicals roundup—21 October 2013

4:49 AM MDT | October 21, 2013 | Deepti Ramesh

AstraZeneca acquires ADC technology firm Spirogen AstraZeneca (London) says that its biologics R&D arm, MedImmune (Gaithersburg, MD), has acquired Spirogen (London), a privately held biotech company focused on antibody-drug conjugate (ADC) technology for use in oncology. MedImmune has also entered into a collaboration agreement with ADC Therapeutics (Lausanne, Switzerland) to jointly develop two of ADC Therapeutics’ ADC programs in preclinical development, AstraZeneca says. MedImmune will also make an equity investment in ADC Therapeutics, which has an...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 



Comments (1) for Pharma/fine chemicals roundup—21 October 2013
1.
Bitte lesen Sie das uber diese Firme aus Rumaenien und dann entscheiden Sie ob verdienen sie aufDeuschemarkt zukommen_
http://insulaindoielii.wordpresss.com/2012/10/11/colon-help-sues-wordpress.
Posted by maria on Friday, October 25, 2013 @ 06:32 AM










 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa